$CATB News
Last published 5y ago
- 5y agoCATBCatabasis Pharmaceuticals Announces New Company Name, Astria Therapeutics, Highlighting New Company FocusBusiness Wire-- Astria Reflects Company's Patient-Focused Mission -- -- Promising Lead Program STAR-0215 is in Preclinical Development to Prevent Attacks in Hereditary Angioedema -- -- Company to Begin Trading Under New Ticker Symbol ATXS on September 9 --
- 5y agoCATBCatabasis Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides a Corporate UpdateBusiness WireCatabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update. "We are focused on advancing the development of our lead program,
- 5y agoCATBCatabasis Pharmaceuticals To Present At Ladenburg Thalmann 2021 Healthcare ConferenceBusiness WireCatabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on its lead program QLS-215, which is in preclinica
- 5y agoALTARVLCATBMNKD+1Thinking about buying stock in Catabasis Pharmaceuticals, Arrival, MannKind, Trevena, or Altimmune?PR NewswireNEW YORK, June 16, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CATB, ARVL, MNKD, TRVN, and ALT. To
- 5y agoCATBCatabasis Pharmaceuticals To Present At Upcoming Investor ConferencesBusiness WireCatabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on its lead program QLS-215, which is in preclinica
- 5y agoCATBCatabasis Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides a Corporate UpdateBusiness Wire-- QLS-215, a Potential Best-in-Class Monoclonal Antibody Inhibitor of Plasma Kallikrein, Progresses in Preclinical Development for the Treatment of Hereditary Angioedema -- -- Strong Cash Position of $146.9M Planned to Fund IND-Enabling Studies, P
- 5y agoCATBLABPXontogeny Announces Launch of Several New Early-Stage Portfolio CompaniesBusiness Wire– Five new drug therapeutic companies supported with strategic and operational guidance and seed capital – – Programs include a diverse portfolio of therapeutic modalities across a wide range of disease areas – Xontogeny LLC, a Boston-bas
- 5y agoCATBCatabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate UpdateBusiness WireBOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided a corporate update.
- 5y agoCATBCatabasis Pharmaceuticals To Present At Upcoming Investor ConferencesBusiness WireBOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, plans to present a corporate overview and provide information about our lead program QLS-215, in preclinical development for the treatment of hereditary angioedema, at the following virtual investor conferences this month:
- 5y agoCATBCatabasis Pharmaceuticals Announces Acquisition of Quellis Biosciences Inc.Business WireBOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that it has acquired Quellis Biosciences Inc. (“Quellis”), a privately-held emerging biopharmaceutical company focused on discovering best-in-class new molecules to treat serious rare diseases. Concurrent with the acquisition of Quellis, Catabasis entered into a definitive agreement ...
- 5y agoMBRXIBIOMACKCATB+1Development of Advanced Novel AML Drugs Target Increasing Cases of Acute Myeloid LeukemiaPR NewswireAcute myeloid leukemia (AML) is a rare and heterogeneous blood cancer with a poor overall prognosis. It affects predominantly older adults with a...
- 6y agoCATBCatabasis Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides a Corporate UpdateBusiness WireBOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2020 and provided a corporate update.
- 6y agoCATBCatabasis Pharmaceuticals Announces Top-Line Results for the Phase 3 PolarisDMD Trial of Edasalonexent in Duchenne Muscular DystrophyBusiness WireBOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that the Phase 3 PolarisDMD trial of edasalonexent in Duchenne muscular dystrophy (DMD) did not meet the primary endpoint, which was a change from baseline in the North Star Ambulatory Assessment (NSAA) over one year of edasalonexent compared to placebo. The secondary ...
- 6y agoCATBCatabasis Pharmaceuticals Presents Information on Edasalonexent, a Potential Foundational Therapy for Duchenne Muscular Dystrophy, at the Virtual 25th International Congress of the World Muscle SocietyBusiness WireBOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today shared information on the edasalonexent program in Phase 3 development for Duchenne muscular dystrophy (DMD) in poster presentations at the Virtual 25th International Congress of the World Muscle Society. The posters include new preclinical research findings supporting potentia ...
- 6y agoCATBCatabasis Pharmaceuticals to Present During the Virtual 25th International Congress of the World Muscle SocietyBusiness WireBOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that it will present information on the edasalonexent program, in Phase 3 development for the treatment of Duchenne muscular dystrophy (DMD), during the 25th International Congress of the World Muscle Society which begins September 28, 2020.
- 6y agoCATBCatabasis Pharmaceuticals Names Noah Clauser Chief Financial OfficerBusiness WireBOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, announced today that it has promoted Noah Clauser to Chief Financial Officer. Mr. Clauser brings close to 20 years of financial experience to this role and has been with Catabasis for 9 years, most recently as Vice President, Finance.
- 6y agoCATBCatabasis Pharmaceuticals to Present at Upcoming Virtual Investor ConferencesBusiness WireBOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, plans to present a corporate overview and provide information about edasalonexent, in Phase 3 development for the treatment of Duchenne muscular dystrophy, at the following virtual investor conferences this month:
- 6y agoCATBCatabasis Pharmaceuticals to Host Virtual KOL Event on Edasalonexent and Duchenne Muscular DystrophyBusiness WireBOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will be holding a virtual key opinion leader (KOL) event to discuss edasalonexent, currently in Phase 3 clinical development for the treatment of Duchenne muscular dystrophy (DMD), on Friday, September 11,.2020 at 9:00am ET.
- 6y agoCATBCatabasis Pharmaceuticals Reports Second Quarter 2020 Financial Results and Reviews Business ProgressBusiness WireBOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2020 and reviewed recent business progress.
- 6y agoCATBCatabasis Pharmaceuticals to Present at Virtual 2020 Wedbush PacGrow Healthcare ConferenceBusiness WireBOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, announced today that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview at the virtual 2020 Wedbush PacGrow Healthcare Conference on Wednesday, August 12, 2020 at 8:00am ET.
- 6y agoCATBCatabasis Pharmaceuticals and Bill & Melinda Gates Medical Research Institute to Study CAT-5571 in Drug-Sensitive and Drug-Resistant TuberculosisBusiness WireBOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, announced today it entered into an agreement with the Bill & Melinda Gates Medical Research Institute (Gates MRI), a non-profit biotechnology organization, to assess CAT-5571 as a potential oral therapy to promote autophagy and clear persistent lung infections in patients with both d ...
- 6y agoCATBCatabasis Pharmaceuticals to Report Second Quarter 2020 Financial Results on Monday, August 10thBusiness WireBOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will report second quarter 2020 financial results after the Nasdaq Global Market close on Monday, August 10, 2020.
- 6y agoCATBCatabasis Pharmaceuticals to Present at Parent Project Muscular Dystrophy Virtual Annual ConferenceBusiness WireBOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, announced today that it will present information on the edasalonexent program in Phase 3 development for the treatment of Duchenne muscular dystrophy (DMD) at the Parent Project Muscular Dystrophy (PPMD) Virtual Annual Conference, which begins Wednesday, July 22, 2020.
- 6y agoCATBCatabasis Joins Russell 3000® IndexBusiness WireBOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, announced today that it has joined the broad-market Russell 3000® Index at the conclusion of the 2020 Russell Indexes annual reconstitution, effective after the US market opened today.
- 6y agoCATBCatabasis Pharmaceuticals Names Ben Harshbarger Senior Vice President, General CounselBusiness WireBOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, announced today that it has named Ben Harshbarger as Senior Vice President, General Counsel. Mr. Harshbarger brings to Catabasis more than 20 years of experience at commercial-stage pharmaceutical and biotechnology companies.
- 6y agoCATBCatabasis Pharmaceuticals Reports First Quarter 2020 Financial Results and Reviews Business ProgressBusiness WireBOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today reported financial results for the first quarter ended March 31, 2020 and reviewed recent business progress.
- 6y agoCATBCatabasis Pharmaceuticals Presents Edasalonexent, a Potential Foundational Therapy for Duchenne Muscular DystrophyBusiness WireBOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today shared information on the edasalonexent program in Phase 3 development for the treatment of Duchenne muscular dystrophy (DMD) in poster presentations at the 2020 Muscular Dystrophy Association (MDA) Virtual Poster Session. The three posters include an analysis of the baseline c ...
- 6y agoCATBCatabasis Pharmaceuticals to Report First Quarter 2020 Financial Results on Tuesday, May 12thBusiness WireBOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will report first quarter 2020 financial results after the Nasdaq Global Market close on Tuesday, May 12, 2020.
- 6y agoCATBCatabasis Pharmaceuticals to Present at 2020 Muscular Dystrophy Association Virtual Poster SessionBusiness WireBOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that it will present information on the edasalonexent program in Phase 3 development for the treatment of Duchenne muscular dystrophy (DMD) at the 2020 Muscular Dystrophy Association (MDA) Virtual Poster Session later this month.
- 6y agoAFMDAPMCATBEPIX+4Solebury Trout Announces Additional Virtual Conference Presentations from Life Science Companies on April 7, 2020ACCESS NewswireSolebury Trout, a boutique investor relations and corporate communications firm, announced today that it will be hosting a fourth day of presentations as part of a Virtual Conference Series featuring leading companies from the life sciences industry. At the event, taking place on April 7, 2020, management teams will present a business overview and highlights using an online, digital meeting format ...
- 6y agoCATBCatabasis Pharmaceuticals to Present at the Upcoming 2020 Solebury Trout Virtual Investor ConferenceBusiness WireBOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, plans to present a corporate overview and provide a business update at the upcoming Solebury Trout Virtual Investor Conference on Tuesday, March 31, 2020 at 12:30pm EDT.
- 6y agoCATBCatabasis Pharmaceuticals to Present During the Muscular Dystrophy Association Virtual Clinical Trials SessionBusiness WireBOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that it will present information on the edasalonexent program in Phase 3 development for the treatment of Duchenne muscular dystrophy (DMD) during the Muscular Dystrophy Association (MDA) Virtual Clinical Trials Session on Tuesday, March 24, 2020.
- 6y agoCATBCatabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Reviews Business ProgressBusiness WireBOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today reported financial results for the fourth quarter and full year ended December 31, 2019 and reviewed recent business progress.
- 6y agoCATBCatabasis Pharmaceuticals to Report Fourth Quarter and Full Year 2019 Financial Results and Recent Corporate Developments on Tuesday, March 10thBusiness WireBOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will report fourth quarter and full year 2019 financial results before the Nasdaq Global Market open on Tuesday, March 10, 2020. Jill C. Milne, Chief Executive Officer, will host a conference call and webcast at 8:30am ET to provide an update on corporate developments and to discuss ...
- 6y agoCATBCatabasis Pharmaceuticals to Present Edasalonexent at the XVIII International Conference on Duchenne and Becker Muscular DystrophyBusiness WireBOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that it will present the edasalonexent program in Phase 3 development for the treatment of Duchenne muscular dystrophy at the XVIII International Conference on Duchenne and Becker Muscular Dystrophy, organized by Parent Project, in Rome, Italy.
- 6y agoCATBCatabasis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Over-Allotment OptionBusiness WireBOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (“Catabasis,” the “Company,” “we,” “our,” or “us”) (NASDAQ: CATB), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of an aggregate of 5,290,000 shares of common stock at a public offering price of $5.00 per share, including 690,000 shares issued upon the exercis ...
- 6y agoCATBCatabasis Pharmaceuticals Announces Proposed Underwritten Public OfferingBusiness WireBOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (“Catabasis,” the “Company,” “we,” “our,” or “us”) (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that it intends to offer its securities in an underwritten public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be comp ...
- 6y agoCATBCatabasis Pharmaceuticals and Duchenne UK Announce Partnership to Evaluate Edasalonexent in a Phase 2 Non-Ambulatory Duchenne Muscular Dystrophy TrialBusiness WireBOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, and Duchenne UK, a charity that seeks to fund and accelerate treatments and a cure for Duchenne muscular dystrophy (DMD), have entered into a partnership for a Phase 2 trial of edasalonexent, a novel NF-kB inhibitor, in non-ambulatory DMD patients. This exploratory Phase 2 trial, whi ...
- 6y agoCATBCatabasis Pharmaceuticals Announces Phase 3 PolarisDMD Trial Enrolled Expected Patient PopulationBusiness WireBOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced the results from an analysis of the baseline characteristics of the Phase 3 PolarisDMD trial of edasalonexent in Duchenne muscular dystrophy (DMD). The analysis shows that overall the patients enrolled in the Phase 3 trial have similar characteristics to the patients ...
- 7y agoCATBCatabasis Pharmaceuticals Reports Third Quarter 2019 Financial Results and Reviews Business ProgressBusiness WireBOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2019 and reviewed recent business progress.
- 7y agoCATBCatabasis Pharmaceuticals to Present Third Quarter 2019 Financial Results and Recent Corporate Developments on Thursday, November 7thBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will report third quarter 2019 financial results before the Nasdaq Global Market open on Thursday, November 7, 2019. Jill C. Milne, Ph.D., Chief Executive Officer, will host a conference call and webcast at 8:30am ET to provide an update on corporate developments and to dis ...
- 7y agoCATBCatabasis Pharmaceuticals to Present at the Child Neurology Society 48th Annual MeetingBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that results from the Phase 2 MoveDMD trial and open-label extension with edasalonexent in boys affected by Duchenne muscular dystrophy (DMD) will be presented at the Child Neurology Society 48th Annual Meeting to be held October 23-26 in Charlotte, North Ca ...
- 7y agoCATBCatabasis Pharmaceuticals Presents Edasalonexent, a Potential Foundational Treatment for Duchenne Muscular DystrophyBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today presented the findings from the MoveDMD trial of edasalonexent. In the Phase 2 MoveDMD trial and open-label extension, edasalonexent slowed disease progression compared to the off-treatment control period and was well tolerated through more than 55 cumulative patient ...
- 7y agoCATBCatabasis Pharmaceuticals Announces the Phase 3 PolarisDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy has Exceeded Target EnrollmentBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, announced today the completion of enrollment for the Phase 3 PolarisDMD trial of edasalonexent in Duchenne muscular dystrophy (DMD). The target enrollment of 125 boys was exceeded due to strong interest from our 40 clinical sites in 8 countries and the support of patient ad ...
- 7y agoCATBCatabasis Pharmaceuticals to Present the MoveDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy at the 24th International Congress of the World Muscle SocietyBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that the Phase 2 MoveDMD trial and open-label extension with edasalonexent in boys affected by Duchenne muscular dystrophy (DMD) will be presented at the 24th International Congress of the World Muscle Society, being held October 1-5, 2019, at the Tivoli Gar ...
- 7y agoCATBCatabasis Pharmaceuticals and the Jain Foundation Announce a Preclinical Research Collaboration to Study Edasalonexent in DysferlinopathyBusiness WireCAMBRIDGE, Mass. & SEATTLE--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, and the Jain Foundation, a non-profit foundation whose mission is to cure muscular dystrophies caused by dysferlin protein deficiency, announced a preclinical research collaboration to study edasalonexent (CAT-1004) in Dysferlinopathy. Dysferlinopathy (Limb-girdle ...
- 7y agoCATBCatabasis Pharmaceuticals Names Andrew A. Komjathy Chief Commercial OfficerBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, announced today that it has named Andrew A. Komjathy as Chief Commercial Officer. Mr. Komjathy brings to Catabasis more than 30 years of experience in commercial operations and sales including extensive experience in rare diseases.
- 7y agoCATBCatabasis Pharmaceuticals Reports Second Quarter 2019 Financial Results and Reviews Business ProgressBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2019 and reviewed recent business progress.
- 7y agoCATBCatabasis Pharmaceuticals Appoints Hugh M. Cole to its Board of DirectorsBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced the appointment of Hugh M. Cole to its Board of Directors. Mr. Cole has more than 20 years of pharmaceutical business development experience and is currently the Chief Business Officer and Head of Corporate Development at Jounce Therapeutics.
- 7y agoCATBCatabasis Pharmaceuticals to Present at 2019 Wedbush PacGrow Healthcare ConferenceBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview at the 2019 Wedbush PacGrow Healthcare Conference on Tuesday, August 13, 2019 at 4:15pm ET at the Parker New York in New York, NY.